July 9, 2020 by admin 0 Comments

DRADS Capital Leads Series C Round for ROKIT Healthcare, a South Korean 4D Bioprinting Company

DRADS Capital announced its investment in ROKIT Healthcare Inc., a South Korean biotechnology company developing innovative 4D bioprinting techniques and applications, in its Series C funding round of undisclosed amount. DRADS Capital is a Boston-based venture capital fund which specializes in making strategic investments in life sciences, biotechnology and artificial intelligence. ROKIT Healthcare Inc. introduces a cutting-edge organ regeneration platform based on 4D printing and clinical diagnosis technology for age-related diseases, such as rheumatoid arthritis and Alzheimer’s disease, to the global anti-aging market. (Graphic: Business Wire)

“ROKIT introduces a cutting-edge organ regeneration platform based on 4D printing and clinical diagnosis technology for age-related diseases, such as rheumatoid arthritis and Alzheimer’s disease, to the global anti-aging market.”

SEOUL, South Korea–(BUSINESS WIRE)–DRADS Capital announced today its investment in ROKIT Healthcare Inc., a South Korean biotechnology company developing innovative 4D bioprinting techniques and applications, in its Series C funding round of undisclosed amount. Founded in 2018, DRADS Capital is a Boston-based venture capital fund which specializes in making strategic investments in life sciences, biotechnology and artificial intelligence (AI). One of its notable founders is Dr. Rudolph E. Tanzi, who is the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard University, Vice-Chair of Neurology and Director of the Genetics and Aging Research Unit at Massachusetts General Hospital (MGH). He was also named to TIME magazine’s list of TIME 100 Most Influential People in the World in 2015.

Nagarajan Pillay, founding Managing Director of DRADS Capital and former Senior Vice President of Pepsi Bottling Franchise, commented on the investment, “We stand behind ROKIT’s fundamental belief that ‘aging is disease’ and their aim to change the world with customized organ regeneration platforms. As the lead investor in ROKIT’s Series C funding round, we believe that ROKIT’s novel organ regeneration technology will dramatically improve clinical therapeutics in the field of wound healing. Their recently published paper in the Diabetes Journal shows how their 4D bioprinter ‘Dr. INVIVO’ — the world’s first sterile, all-in-one 4D organ regenerator — is used to regenerate skin as a treatment for diabetic foot ulcers, negating the need for amputation and skin grafting. It is without a doubt that ROKIT Healthcare Inc. will make great strides under the leadership of Chairman Seokhwan You in the era of organ regeneration.” Dr. Tanzi also expressed his excitement about ROKIT, stating “We are thrilled and honored to be aligned with ROKIT Healthcare and the tremendous promise of their regenerative bioprinting technologies.”

Chairman You, the founder and CEO of ROKIT Healthcare Inc., stated: “ROKIT introduces a cutting-edge organ regeneration platform based on 4D printing and clinical diagnosis technology for age-related diseases, such as rheumatoid arthritis and Alzheimer’s disease, to the global anti-aging market.” Chairman You, who is also the former CEO of Celltrion Healthcare, a South Korean biopharmaceutical company valued at $14 billion today, added: “With our extensive experiences in the biomedical industry, ROKIT Healthcare will make every effort to continue growing as an innovative global company by expanding its business domain ranging from personalized organ regeneration to anti-aging markets. This will be headed by our revolutionary Diabetic Foot Ulcer Platform, DFURegen, which will combat this incurable disease with a global market share of about USD 40 billion.” The company plans to go public in 2021.

June 25, 2020 by admin 0 Comments

ROKIT Healthcare Reveals World’s First All-in-One Bioprinting Platform with Built-in Bioreactor Chamber, Plasma Sterilizer and 6 Rotary Printheads: Dr. INVIVO 4D6

ROKIT Healthcare announced the launch of the Dr. INVIVO 4D6, a bioreactor-based bioprinting platform with a built-in cell incubator and low-temperature plasma sterilizer as the first of its kind. It is designed and built with the vision of in-hospital manufacturing and offers a controlled cellular environment in aseptic conditions in combination with the complex biofabrication technologies of six rotary printheads. ROKIT Healthcare is a South Korea-based regenerative medicine solutions company that develops hardware, software, and clinical application platforms employing 4D bioprinting technology for customized human organ and tissue regeneration.

Chief Executive Officer at ROKIT Healthcare, Seok Hwan You, explains: “Bioprinting right by the bedside inside the operating theatre means minimized time, risks, and costs in the transfer of patient cells to the bioprinter and in the transfer of printed tissues back to the patient. It is a new kind of point-of-care, personalized healthcare solution that maximizes the benefits of autologous regenerative medicine technologies. Dr. INVIVO 4D6, which we call the Organ Regenerator, is designed to pave the way with features that have been added after feedback from physicians and scientists.”

Features on the Dr. INVIVO 4D6 from ROKIT Healthcare

Achieving three-dimensional architecture is just one of several factors to consider in tissue engineering. Cell environment factors, like incubation temperature, oxygen/carbon dioxide level, and humidity are key to successful human tissue and organ development with optimal cell viability and functionality. Moving beyond the capacity to dispense cells and biomaterials with multiple printheads, Dr. INVIVO 4D6 offers an integrated system to meet clinical needs in human tissue engineering and its translational applications.

Dr. INVIVO 4D6 optimizes tissue engineering and regenerative medicine research with:

  1. Built-in cell incubator with temperature, humidity and CO2 control
  2. 6 printheads for complex tissue fabrication with hydrogels, filaments, polymer pellets, and diverse FDA-approved materials
  3. Complete particle control with circular air flow generation technology, much like a biosafety cabinet
  4. High-throughput to the max with up to 384-well tissue screening and assay development

Translation of Bioprinting in the Operating Room

In addition to being a bioprinter manufacturer, ROKIT Healthcare works as a medical contractor that partners with state agencies, biotech firms and academic research centers to develop applications for bioprinting technology in the hospital operating room. ROKIT Healthcare has been awarded a $3 million grant by the South Korean government to co-develop an in-situ 3D bioprinting system for skin regeneration. Since 2019, ROKIT Healthcare has partnered with specialty plastic surgery hospitals around the world to offer 3D scan-print skin regeneration platforms for patients suffering from chronic diabetic foot ulcers and burns. The company has completed clinical studies in India and Korea.

Founded in 2012 and active in more than 50 countries, the company is advancing the scientific and healthcare revolution in regenerative medicine by providing on-demand human tissue manufacturing solutions in vivo and in vitro.

What do you think of the Dr. INVIVO 4D6 from ROKIT Healthcare? Let us know in a comment below or on our Facebook and Twitter pages! Sign up for our free weekly Newsletter, all the latest news in 3D printing straight to your inbox!

June 1, 2020 by admin 0 Comments

All About Extracellular Marix, And its application

ROKIT Open Innovation
All About Extracellular Marix, And its application
- 2020. 06. 12. FRI. 11:00 AM -
OVERVIEW

"Welcome to ROKIT & Calia Webinar"

This webinar will explain what is Extracellular Matrix,
what are the research areas ECM is applied,
and what are the limitations of current ECM products and the solution to it.

* This webinar is hosted by ROKIT Healthcare INC and CALIA

Check out the webinars for more details.
SPEAKER

Joshua Jaeyun Kim, PhD

  • HumaTein/Bioink SBU President

Career Highlight

  • Ph.D., Dept of Biomedical Engineering, Boston University
  • Postdoctoral Research Associate, Boston University
INFORMATION
Subject
Date
Live Platform
All About Extracellular Marix, And its application
2020.06.12. FRI 11:00 AM
ZOOM
INVITATION
Please RSVP today, we will send you ZOOM link soon!

Privacy Policy

Collection of Information : Name, Email, Institution, Dept Name Purpose of Collection : Contact Period of Use : In principle, after the purpose of collecting and using personal information is achieved, such information shall be destroyed without delay. However, personal information may be kept for a certain period as specified in the relevant statutes, if it is necessary to preserve it according to the provisions of the relevant statutes, as follows. - Records on consumer complaints or dispute handling : 3 years (Law on Consumer Protection in Electronic Commerce, etc.) - Agree to collect and use of personal information above. (you can inquire after consent)

ROKIT HEALTHCARE is a 4D Bioprinting and Biotechnology company based in South Korea and is committed to bettering humanity through our contributions to the field of regenerative medicine.
Question
ROKIT Healthcare INC. HYEJOO SON

July 11, 2017 by admin 0 Comments

A portable, low-cost, 3D-printed main magnetic field system for magnetic imaging

Authors
Iksung Kang
Abstract
In this paper, a portable, low-cost, 3D-printed system for main magnetic field is proposed to suggest a solution for accessibility problems of current magnetic imaging systems, e.g. MRI scanner, their size and cost. The system consists of twelve pairs of NdFeB N35 permanent magnets arranged in a Halbach array in a 3D-printed, cylindrical container based on FEM simulation results by COMSOL Multiphysics 4.4b. Its magnetic field homogeneity and field strength were measured by Hall sensors, WSH-135 XPAN2 by Wilson Semiconductor, and the container was printed by 3DISON H700 by Rokit. The system generated a 5-mm imaging quality FOV and main magnetic field of 120 mT with a 12 % error in the field strength. Also, a hundred dollar was enough for the manufacture of the system with a radius of 6 cm and height of 10 cm. Given the results, I believe the system will be useful for some magnetic imaging applications, e.g. EPRI and low-field MRI.